Antibody-drug Conjugate ABBV-399
Semantic Scholar uses AI to extract papers important to this topic.
3011Background: Telisotuzumab vedotin (ABBV-399; teliso-v [T]) is a c-Met–targeted antibody and MMAE drug conjugate. Activity of… Expand 9075Background: Lung-MAP is a platform trial to assess targeted therapies in SCC. S1400K was designed to evaluate the response to… Expand 9023Background: c-Met overexpression (OE) and MET amplification (amp) are prognostic of poor outcome for non-small cell lung… Expand PURPOSE
This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug… Expand 2509Background: The c-Met receptor is overexpressed in ~50% of pts with NSCLC. ABBV-399 is a first-in-class ADC composed of ABT… Expand Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted… Expand 2510Background: The c-Met receptor is overexpressed in multiple tumors. ABBV-399 is a first-in-class antibody-drug conjugate (ADC… Expand